Geographic Atrophy (GA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Geographic Atrophy Emerging Therapy and TPP Insights

Thelansis’s “Geographic Atrophy (GA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Geographic Atrophy Overview

Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration characterized by progressive loss of retinal tissue and permanent visual impairment. A major therapeutic milestone came in 2023 with the approval of pegcetacoplan and avacincaptad pegol, the first treatments specifically designed to slow GA lesion growth by inhibiting the complement pathway. Their impact, however, has exposed an important gap between anatomical and functional outcomes: clinical trials consistently showed slower lesion growth, but conventional measures of visual acuity have not demonstrated equally consistent benefit. Emerging real-world evidence adds further complexity, with studies reporting meaningful treatment attrition alongside evidence that some patients experience slowed structural progression while maintaining relatively stable vision. Conversion to neovascular AMD remains an important safety consideration requiring monitoring. These limitations are reshaping development toward treatments that preserve functional vision, reduce injection burden, or target the disease through complementary mechanisms. For stakeholders, GA illustrates that demonstrating structural efficacy is only the first step; durable functional benefit, treatment persistence, and real-world safety increasingly determine therapeutic value.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)